204 related articles for article (PubMed ID: 33124143)
1. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
[TBL] [Abstract][Full Text] [Related]
3. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes.
Yen FS; Yang YC; Hwu CM; Wei JC; Huang YH; Hou MC; Hsu CC
Liver Int; 2020 May; 40(5):1089-1097. PubMed ID: 31960563
[TBL] [Abstract][Full Text] [Related]
4. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
[TBL] [Abstract][Full Text] [Related]
5. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
6. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
Yen FS; Lai JN; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
BMC Gastroenterol; 2021 Jun; 21(1):263. PubMed ID: 34118892
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
Starner CI; Schafer JA; Heaton AH; Gleason PP
J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
Yen FS; Hou MC; Cheng-Chung Wei J; Shih YH; Hsu CY; Hsu CC; Hwu CM
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1255-1264.e18. PubMed ID: 37331413
[TBL] [Abstract][Full Text] [Related]
9. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
Yen FS; Lai JN; Wei JC; Chiu LT; Hwu CM; Hou MC; Hsu CC
PLoS One; 2020; 15(12):e0243783. PubMed ID: 33315940
[TBL] [Abstract][Full Text] [Related]
10. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
11. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
12. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
13. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
[TBL] [Abstract][Full Text] [Related]
15. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
[TBL] [Abstract][Full Text] [Related]
16. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan.
Hsiao FY; Tsai YW; Wen YW; Chen PF; Chou HY; Chen CH; Kuo KN; Huang WF
Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):786-91. PubMed ID: 20607752
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus.
Yen FS; Wang HC; Pan CW; Wei JC; Hsu CC; Hwu CM
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31544207
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinedione Use in Individuals With Type 2 Diabetes and Chronic Obstructive Pulmonary Disease.
Yen FS; Wei JC; Yang YC; Hsu CC; Hwu CM
Front Med (Lausanne); 2021; 8():729518. PubMed ID: 34957135
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus.
Lee SE; Nam H; Choi HS; Kim H; Kyoung DS; Kim KA
Diabetes Metab J; 2022 Jul; 46(4):567-577. PubMed ID: 35130688
[TBL] [Abstract][Full Text] [Related]
20. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
Habib ZA; Tzogias L; Havstad SL; Wells K; Divine G; Lanfear DE; Tang J; Krajenta R; Pladevall M; Williams LK
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):437-47. PubMed ID: 19235778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
